product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD73 Monoclonal Antibody (eBioTY/11.8 (TY/11.8)), eBioscience™
catalog :
14-0731-82
quantity :
100µg
price :
US 107
clonality :
monoclonal
host :
rat
conjugate :
nonconjugated
clone name :
eBioTY/11.8 (TY/11.8)
reactivity :
mouse
application :
immunohistochemistry, flow cytometry
more info or order :
citations: 20
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
| |
| |
| |
| |
| |
| |
Kobie J, Shah P, Yang L, Rebhahn J, Fowell D, Mosmann T. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol. 2006;177:6780-6 pubmed
| |
Yang L, Kobie J, Mosmann T. CD73 and Ly-6A/E distinguish in vivo primed but uncommitted mouse CD4 T cells from type 1 or type 2 effector cells. J Immunol. 2005;175:6458-64 pubmed
| |
Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood. 2005;106:4057-65 pubmed
| |
Yamashita Y, Hooker S, Jiang H, Laurent A, Resta R, Khare K, et al. CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur J Immunol. 1998;28:2981-90 pubmed
|
product information
Product Type :
Antibody
Product Name :
CD73 Monoclonal Antibody (eBioTY/11.8 (TY/11.8)), eBioscience™
Catalog # :
14-0731-82
Quantity :
100µg
Price :
US 107
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Rat
Reactivity :
Mouse
Applications :
Flow Cytometry: 0.06 µg/test, Immunohistochemistry: Assay-Dependent
Species :
Mouse
Clone :
eBioTY/11.8 (TY/11.8)
Isotype :
IgG1
Storage :
4° C
Description :
CD73 (Ecto-5-prime-nucleotidase, 5-prime-ribonucleotide phosphohydrolase) catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred substrate being AMP. CD73 consists of a dimer of 2 identical 70 kDa subunits bound externally to the plasma membrane by a glycosyl phosphatidyl inositol linkage. CD73 is used as a marker of lymphocyte differentiation. Consequently, a deficiency of CD73 occurs in a variety of immunodeficiency diseases. Other forms of 5-prime nucleotidase exist in the cytoplasm and lysosomes and can be distinguished from CD73 by their substrate affinities, requirement for divalent magnesium ion, activation by ATP, and inhibition by inorganic phosphate. The CD73 gene has been localized to 6q14-q21 by immunofluorescence and a study of a panel of human x mouse hybrids that contained fragments of chromosome 6 as translocations. Defects in the CD73 gene can lead to the calcification of joints and arteries, and intestinal tuberculosis. Two transcript variants encoding different isoforms of CD73 have been found.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 0.06 µg/test, Immunohistochemistry: Assay-Dependent
Aliases :
2210401F01Rik; 5' nucleotidase, ecto; 5'-NT; 5'-nucleotidase; 5'-nucleotidase ecto; 5'-nucleotidase, ecto (CD73); AI447961; CALJA; CD73; E5NT; Ecto-5'-nucleotidase; eN; eNT; NT; Nt5; NT5E; Nte; Purine 5-Prime-Nucleotidase
more info or order :
company information

Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
related products
browse more products
- CD74 Monoclonal Antibody (VIC-Y1), eBioscience™ | 14-0747-80
- CD74 Monoclonal Antibody (VIC-Y1), eBioscience™ | 14-0747-82
- CD79a Monoclonal Antibody (24C2.5), eBioscience™ | 14-0791-80
- CD79a Monoclonal Antibody (24C2.5), eBioscience™ | 14-0791-82
- CD79b Monoclonal Antibody (CB3-1), eBioscience™ | 14-0793-82
questions and comments